VA
CNTX icon

Verdad Advisers’s Context Therapeutics CNTX Stock Holding History

Verdad Advisers’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8K Buy
+33,900
New +$68.7K 0.02% 208

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Verdad Advisers's CNTX Position: Q2 2026 in Review

Verdad Advisers opened a new position in Context Therapeutics (CNTX) in Q2 2026: 33,900 shares worth $18.8K. The stake represents 0.02% of the portfolio and ranks #208 among its holdings.

79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Verdad Advisers held 33,900 shares of Context Therapeutics worth $18.8K as of Q2 2026.
  • Context Therapeutics was a new Verdad Advisers position in Q2 2026.
  • Context Therapeutics made up 0.02% of Verdad Advisers's portfolio in Q2 2026, its #208 holding.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.